Related Experiment Video
Updated: May 9, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Prognosis of morbid obesity patients with advanced heart failure
Vijaiganesh Nagarajan1, Clay A Cauthen, Randall C Starling
1Department of Hospital Medicine, Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Insights
The obesity paradox may not apply to morbidly obese patients with advanced heart failure. Morbid obesity is linked to a higher risk of mortality and transplantation, challenging previous findings.
Area of Science:
- Cardiology
- Obesity Medicine
Background:
- The obesity paradox suggests better outcomes for obese patients in certain conditions, including heart failure.
- This study investigates whether this paradox holds true for individuals with morbid obesity and advanced heart failure.
Purpose of the Study:
- To examine the relationship between body mass index (BMI) categories and prognosis in patients with advanced heart failure.
- To determine if morbid obesity (BMI ≥40 kg/m²) is associated with worse outcomes compared to obesity (BMI 30.1-40 kg/m²) and non-obesity (BMI ≤30 kg/m²).
Main Methods:
- A cohort of 501 consecutive patients with advanced heart failure undergoing heart transplant evaluation was analyzed.
- Patients were stratified into three BMI groups: nonobese, obese, and morbidly obese.
- Survival rates and risk of all-cause mortality/transplantation were compared across groups using univariate and multivariate analyses.
Main Results:
- Unadjusted event-free survival rates were significantly lower in the morbidly obese group (28.6%) compared to obese (57.4%) and nonobese (48.4%) groups.
- Both nonobese and morbidly obese patients faced a significantly higher risk of mortality/transplantation compared to the obese group, even after adjusting for confounding factors.
- The morbidly obese group exhibited fewer cardiovascular risk factors, suggesting these factors may not explain the observed survival differences.
Conclusions:
- The obesity paradox is present in advanced heart failure but does not extend to morbidly obese patients.
- Morbid obesity is associated with a poorer prognosis in advanced heart failure, independent of traditional cardiovascular risk factors.
- Clinical management strategies for advanced heart failure should consider the distinct risks associated with morbid obesity.
Abstract:
Obese patients have been noted to have better prognosis in many conditions including heart failure. We hypothesize that this favorable prognosis for obesity may not be seen in patients with morbid obesity and advanced heart failure. A total of 501 consecutive patients with advanced heart failure referred for heart transplant evaluation to the Cleveland Clinic were studied. Patients were categorized into 3 groups based on their body mass index score as nonobese (≤30 kg/m(2) ), obese (30.1-40 kg/m(2) ), and morbidly obese (≥40 kg/m(2) ). There were fewer cardiovascular risk factors in the morbidly obese group. Unadjusted event-free survival rates were 48.4%, 57.4%, and 28.6% in the nonobese, obese, and morbidly obese groups, respectively (P=.02). In univariate analysis, both the nonobese group (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.09-1.91; P=.01) and the morbidly obese group (HR, 2.46; 95% CI, 1.40-4.30; P=.002) had significantly higher risk of all-cause mortality/transplantation compared with the obese group. This difference persisted in multivariate analysis after adjustment for confounding factors. Our study re-emphasizes the presence of an obesity paradox even in patients with very advanced heart failure. This favorable prognosis, however, may not be relevant in patients with morbidly obesity. Cardiovascular risk factors may not contribute to this phenomenon.
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure VII: Nursing Interventions
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure I: Introduction
